Investigating the effects of lithium on phosphate levels and mood disorders
Anergia-anhedonia by Lithium-induced Phosphorus Diabetes
University Hospital, Strasbourg, France · NCT06111664
This study is trying to see how lithium treatment affects phosphate levels and mood in people with mood disorders who have been on the medication for more than six months.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06111664 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of hypophosphatemia, phosphate diabetes, and subjective symptoms linked to lithium treatment in patients who have been on lithium for over six months. The research will involve monitoring outpatient individuals at the University Hospital in Strasbourg, France, focusing on those experiencing mood disorders. By analyzing data collected during routine follow-ups, the study seeks to establish a connection between lithium-induced phosphate changes and reported symptoms of fatigue and emotional blunting.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been stabilized on lithium for more than six months.
Not a fit: Patients who are not on lithium or those with conditions that prevent them from participating, such as being under judicial protection, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients on lithium, potentially alleviating debilitating symptoms associated with its use.
How similar studies have performed: While there is limited published research on the specific link between lithium-induced phosphate diabetes and subjective symptoms, the study builds on existing knowledge of chronic fatigue syndromes and phosphate metabolism.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major subject (≥ 18 years old) * Man or woman * Subject balanced on Li+ (\> 6 months, regardless of the underlying pathology). * Outpatient monitoring by one of the members of CEDRA (Alsace expert center for resistant depression). * Subject not opposing, after information, the reuse of their data for the purposes of this research Exclusion Criteria: * Subject having expressed opposition to participating in the study * Subject under judicial protection * Subject under guardianship or curatorship
Where this trial is running
Strasbourg
- CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Jack FOUCHER, MD, PhD
- Email: jack.foucher@chru-strasbourg.fr
- Phone: 33 3 88 11 69 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mood Disorders, Diabetes, Phosphate, Anergia-anhedonia, Lithium